RE:Companies before BTDOur market cap is worth nothing, considering where we're at now (43% into a Ph. 2, with Ph. 1b patients #5 and #6 cancer-free for 540+ consecutive days with only one dose and that we have captured the attention of PHAC-NML with this same molecule for the last step of the preclinical stage).
This is clearly a clinical data driven stock, no doubt. And we need clearer data on both NMIBC and COVID-19 indications. Then, if this data shows we can shift any competition, we're off the gates.
Trailblazers sometimes take longer to obtain the recognition they deserve. But clinical data is pivotal.
Now, 2 important milestones are within reach; NMIBC and COVID-19.
Just imagine if NML confirms that:
Feb. 7, 2022 - "These results have now laid the groundwork for the next phase of the CRA, which is evaluating the Theralase® COVID-19 vaccine in the ability to prevent animals from contracting COVID-19, when exposed to the virus."
and if the 11 NMIBC patients that had pending results following their 2nd dose were all CR @270-days.
But we need these type of results, otherwise, the potential is not confirmed.